4.4. international germ cell cancer collaborative group (igcccg) classification prognostic risk groups metastatic germ cell cancer. 1997 igcccg defined prognostic risk-factor system metastatic gct based identification clinically independent adverse factors . classification revalidated contemporary cohort metastatic tgct treated cisplatin/etoposide based first-line chemotherapy . compared 1997 figures, five-year progression-free survival (pfs) nsgct patients unchanged good- intermediate-risk, significantly improved poor-risk patients (from 41% 54%). five-year overall survival (os) substantially better groups. addition traditional components igcccg risk-prognostic groups previously described, older age (linear association) lung metastases confirmed negative factors pfs . sgct, revalidation igcccg classification showed five-year pfs increased 89% 79% good- intermediate-risk patients corresponding os rates 95% 88%. testicular lactate dehydrogenase (ldh) 2.5 times upper limit normal (uln) identified possible adverse prognostic factor regard reduced three-year pfs, however overall three-year survival affected . table 4: prognostic-based staging system metastatic germ cell cancer (igcccg) * prognostic-based staging system metastatic germ cell cancer (igcccg)good-prognosis groupnsgct5-year pfs 90%5-year survival 96%all following criteria:• testis/retro-peritoneal primary• non-pulmonary visceral metastases• afp < 1,000 ng/ml• β-hcg < 5,000 iu/l (1,000 ng/ml)• ldh < 1.5 x ulnsgtc5-year pfs 89%5-year survival 95%all following criteria:• primary site• non-pulmonary visceral metastases• normal afp• β-hcg• ldhintermediate-prognosis groupnsgct5-year pfs 78%5-year survival 89%any following criteria:• testis/retro-peritoneal primary• non-pulmonary visceral metastases• afp 1,000 - 10,000 ng/ml or• β-hcg 5,000 - 50,000 iu/l or• ldh 1.5 - 10 x ulnsgct5-year pfs 79%5-year survival 88%all following criteria:• primary site• non-pulmonary visceral metastases• normal afp• β-hcg• ldhpoor-prognosis groupnsgct5-year pfs 54%5-year survival 67%any following criteria:• mediastinal primary• non-pulmonary visceral metastases• afp > 10,000 ng/ml or• β-hcg > 50,000 iu/l (10,000 ng/ml) or• ldh > 10 x ulnsgctno patients classified poor-prognosis * pre-chemotherapy serum tumour markers assessed immediately prior administration chemotherapy (same day).afp = alpha-fetoprotein; β-hcg = human chorionic gonadotrophin; ldh = lactate dehydrogenase; pfs = progression-free survival.